vascular endothelial growth factor receptor การใช้

• Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 ( VEGFR-2 ).
• Lymphatic-specific vascular endothelial growth factors VEGF-C and VEGF-D function as ligands for the vascular endothelial growth factor receptor 3 ( VEGFR-3 ).
• Extracts from " P . campestris " leaves have been shown to inhibit the interaction between Vascular endothelial growth factor A and Vascular endothelial growth factor receptor 1.
• Examples of promoters include Vascular Endothelial Growth Factor ( VEGF ) and fibroblast growth factor ( FGF ) Examples of inhibitors include Vascular Endothelial Growth Factor Receptor 1, etc.
• This process is mediated by a high-affinity interaction with VEGFR2 ( vascular endothelial growth factor receptor ) which leads to increased levels of tumor suppressor gene called " PEG3 ".
• These include all receptors for platelet-derived growth factor ( PDGFR ) and vascular endothelial growth factor receptors ( VEGFR ), which play a role in both tumor angiogenesis and tumor cell proliferation.
• If ?-catenin is over-expressed, too many cells undergo EMT . The vascular endothelial growth factor receptor ( VEGFR ) is also necessary for the PMCs to function as mesenchymal cells.
• These include all receptors for platelet-derived growth factor ( PDGF-Rs ) and vascular endothelial growth factor receptors ( VEGFRs ), which play a role in both tumor angiogenesis and tumor cell proliferation.
• He and his team discovered that inhibiting a key player in the signaling system ( called vascular endothelial growth factor receptor or VEGFR ) suppresses the generation of blood vessels in tumors and slows down cancer cell growth.
• An example is pegdinetanib ( Angiocept ), an antagonist of vascular endothelial growth factor receptor 2 ( VEGFR-2 ), which has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007.
• The first of these agents to negotiate the approval process is vandetanib, a tyrosine kinase inhibitor that targets the RET proto-oncogene, 2 subtypes of the vascular endothelial growth factor receptor, and the epidermal growth factor receptor.
• "' Apatinib "', also known as "'YN968D1 "', is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 ( VEGFR2, also known as KDR ).
• Furthermore, microbubbles can be conjugated to markers such as activated glycoprotein IIb / IIIa ( GPIIb / IIIa ) receptors on platelets and clots, ? v ? 3 integrin, as well as vascular endothelial growth factor receptors ( VEGFR ), in order to provide molecular visualization.
• The multitargeted tyrosine kinase inhibitor sorafenib ( trade name Nexavar ), which inhibits vascular endothelial growth factor receptor ( VEGFR ), platelet-derived growth factor receptor, raf, c-kit, and flt-3, has been shown to inhibit HCC-induced proliferation and angiogenesis.
• This potential is indicated by the presence of some known lymphatic markers such as " Vascular endothelial growth factor receptor-3 ( Vegfr3 or Flt4; a receptor for VegfC and VegfD ) ", and also the presence of " Lyve1 ", which is a lymphatic specific hyluronan receptor.